241 related articles for article (PubMed ID: 19575689)
21. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
McGowan I; Gomez K; Bruder K; Febo I; Chen BA; Richardson BA; Husnik M; Livant E; Price C; Jacobson C;
AIDS; 2011 May; 25(8):1057-64. PubMed ID: 21505316
[TBL] [Abstract][Full Text] [Related]
22. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495
[TBL] [Abstract][Full Text] [Related]
23. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
[TBL] [Abstract][Full Text] [Related]
24. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days.
Doh AS; Ngoh N; Roddy R; Lai JJ; Linton K; Mauck C
Contraception; 2007 Sep; 76(3):245-9. PubMed ID: 17707724
[TBL] [Abstract][Full Text] [Related]
25. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.
Friedland BA; Stoner M; Chau MM; Plagianos MG; Govender S; Morar N; Altini L; Skoler-Karpoff S; Ahmed K; Ramjee G; Monedi C; Maguire R; Lähteenmäki P
AIDS Behav; 2016 Nov; 20(11):2565-2577. PubMed ID: 26204987
[TBL] [Abstract][Full Text] [Related]
26. Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.
Vallely A; Fitzgerald L; Fiya V; Aeno H; Kelly A; Sauk J; Kupul M; Neo J; Millan J; Siba P; Kaldor JM
BMC Res Notes; 2012 Nov; 5():613. PubMed ID: 23116431
[TBL] [Abstract][Full Text] [Related]
27. The need for a "condoms-only" control group in microbicide trials.
Jones H; van de Wijgert J; Kelvin E
Epidemiology; 2003 Jul; 14(4):505; author reply 505-6. PubMed ID: 12843779
[No Abstract] [Full Text] [Related]
28. Women's interest in vaginal microbicides.
Darroch JE; Frost JJ
Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
[TBL] [Abstract][Full Text] [Related]
29. Couples' acceptability of the SILCS diaphragm for microbicide delivery.
Frezieres RG; Walsh T; Kilbourne-Brook M; Coffey PS
Contraception; 2012 Jan; 85(1):99-107. PubMed ID: 22067809
[TBL] [Abstract][Full Text] [Related]
30. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
Perino A; Consiglio P; Maranto M; De Franciscis P; Marci R; Restivo V; Manzone M; Capra G; Cucinella G; Calagna G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
[TBL] [Abstract][Full Text] [Related]
31. Acceptability of a microbicide among women and their partners in a 4-country phase I trial.
Bentley ME; Fullem AM; Tolley EE; Kelly CW; Jogelkar N; Srirak N; Mwafulirwa L; Khumalo-Sakutukwa G; Celentano DD
Am J Public Health; 2004 Jul; 94(7):1159-64. PubMed ID: 15226137
[TBL] [Abstract][Full Text] [Related]
32. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
Barnhart KT; Rosenberg MJ; MacKay HT; Blithe DL; Higgins J; Walsh T; Wan L; Thomas M; Creinin MD; Westhoff C; Schlaff W; Archer DF; Ayers C; Kaunitz A; Das S; Moench TR
Obstet Gynecol; 2007 Sep; 110(3):577-86. PubMed ID: 17766603
[TBL] [Abstract][Full Text] [Related]
33. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
[TBL] [Abstract][Full Text] [Related]
34. Test of new vaginal microbicide gel show promise for women.
AIDS Read; 2008 Apr; 18(4):165-6. PubMed ID: 18467997
[No Abstract] [Full Text] [Related]
35. Young Women's use of a microbicide surrogate: the complex influence of relationship characteristics and perceived male partners' evaluations.
Tanner AE; Fortenberry JD; Zimet GD; Reece M; Graham CA; Murray M
Arch Sex Behav; 2010 Jun; 39(3):735-47. PubMed ID: 19224355
[TBL] [Abstract][Full Text] [Related]
36. Microbicide preference among young women in California.
Holt BY; Morwitz VG; Ngo L; Harrison PF; Whaley KJ; Pettifor A; Nguyen AH
J Womens Health (Larchmt); 2006 Apr; 15(3):281-94. PubMed ID: 16620187
[TBL] [Abstract][Full Text] [Related]
37. Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.
Weinrib R; Browne EN; Shapley-Quinn MK; van der Straten A; Beksinska M; Mgodi N; Musara P; Mphili N; Schwartz JL; Ju S; Hanif H; Montgomery ET;
AIDS Behav; 2020 Feb; 24(2):637-647. PubMed ID: 31254190
[TBL] [Abstract][Full Text] [Related]
38. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
Ballagh SA; Brache V; Mauck C; Callahan MM; Cochon L; Wheeless A; Moench TR
Contraception; 2008 Feb; 77(2):130-7. PubMed ID: 18226678
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial to determine the distribution of four topical gel formulations in the human vagina.
Barnhart K; Kulp JL; Rosen M; Shera DM
Contraception; 2009 Apr; 79(4):297-303. PubMed ID: 19272499
[TBL] [Abstract][Full Text] [Related]
40. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.
Giguere R; Carballo-Diéguez A; Ventuneac A; Mabragaña M; Dolezal C; Chen BA; Kahn JA; Zimet GD; McGowan I
Cult Health Sex; 2012; 14(2):151-66. PubMed ID: 22084840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
